-
Gene Therapy Education Program – A CHS comprehensive information program
The hemophilia community has been waiting for gene therapy for years; many hoped it would be a cure. Quantitative and qualitative results from late stages of clinical trials for...
Our continuing efforts to raise awareness about women and bleeding disorders
For almost 25 years, the CHS has played a key role in raising awareness about bleeding disorders that affect women. In 2012, to ensure the continuity and effectiveness of...
Health Canada approves Hemgenix gene therapy for hemophilia B
Ottawa, October 26, 2023 – Health Canada has authorized Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of hemophilia B. Hemgenix is indicated for the treatment of adults with...
Patient satisfaction survey
The Canadian bleeding disorder treatment centres participed in a rigorous self-assessment of their services from November 2022 to February 2023. IT IS NOW TIME TO HEAR FROM PATIENTS AND...
